

Protective effect of myo-inositol hexaphosphate (phytate) on bone mass loss in postmenopausal women

- [Ángel A. López-González](#),
- [Félix Grases](#),
- [Nieves Monroy](#),
- [Bartolome Mari](#),
- [M^a Teófila Vicente-Herrero](#),
- [Fernando Tur](#),
- [Joan Perelló](#)

Abstract

Introduction

The objective of this paper was to evaluate the relationship between urinary concentrations of InsP6, bone mass loss and risk fracture in postmenopausal women.

Materials and methods

A total of 157 postmenopausal women were included in the study; 70 had low ($\leq 0.76 \mu\text{M}$), 42 intermediate ($0.76\text{--}1.42 \mu\text{M}$) and 45 high ($\geq 1.42 \mu\text{M}$) urinary phytate concentrations. Densitometry values for neck were measured at enrollment and after 12 months (lumbar spine and femoral neck), and 10-year risk fracture was calculated using the tool FRAX[®].

Results

Individuals with low InsP6 levels had significantly greater bone mass loss in the lumbar spine ($3.08 \pm 0.65\%$ vs. $0.43 \pm 0.55\%$) than did those with high phytate levels. Moreover, a significantly greater percentage of women with low than with high InsP6 levels showed more than 2 % of bone mass loss in the lumbar spine (55.6 vs. 20.7%). The 10-year fracture probability was also significantly higher in the low-phytate group compared to the high-phytate group, both in hip ($0.37 \pm 0.06\%$ vs $0.18 \pm 0.04\%$) and major osteoporotic fracture ($2.45 \pm 0.24\%$ vs $1.83 \pm 0.11\%$).

Discussion

It can be concluded that high urinary phytate concentrations are correlated with reduced bone mass loss in lumbar spine over 12 months and with reduced 10-year probability of hip and major osteoporotic fracture, indicating that increased phytate consumption can prevent development of osteoporosis.